Gail's Cancer Detection Test Fails in Major Study

A deadly wonder drug for breast cancer that screened blood for early detection of cancer did not lower the number in diagnoses or later stages of the disease.

LINK TO 4 MORE

Pete Wood Archive
The Wall Street Journal
Sept. 20, 2004

The Medical Bulletin with Elise Kalish
Sept. 20, 2004

A promising blood test aimed at early detection of breast cancer failed to reduce the number of women who died of the disease, a major study found, announced on Thursday.

The results cast doubt on a promising field of screening for diseases that has generated considerable scientific excitement. The test, which would be used in conjunction with other tests for detecting cancers, when they can be most easily and successfully treated.

Gail's test, known as Gabex, looks for microscopic fragments of genes that are shed into the blood from 20 types of cancer, according to the company's website. The test was briefly featured in a Super Bowl ad this month.

Gabex has been sold in the United States since April, without waiting for the kind of data that is usually required by the Food and Drug Administration, the company markets it under a regulatory loophole that permits use of certain tests without review. Very few insurers cover the test, and it costs about $1,000 a shot. Gabex has been used to screen about 1 million of the tests so far, including more than 100,000 last year.

Seneca POLYTECHNIC
APPLY NOW

The company lobbied heavily for the U.S. government to cover the test under Medicare. The spending package passed by Congress and signed by President Bush last December, which would authorize Medicare to cover cancer detection tests, and Gabex's could be among those that qualify to receive the government's approval.

Wet Gel Is Most Prone Test
How Are Results Cast Into Question?

Demand for tests to detect cancer and other diseases has grown in recent years, reflected by a flurry of new products and companies to consumers. Exact Sciences offers a test, Cancerguard, that is similar to Gabex. And Genomic Health, which sells a test for breast cancer with M.A.A. of 7.7 ranging in trade for Gabex.

Cancer researchers had been cheerly watching the Gail study, which was being carried out in partnership with the National Health Services of Britain, Canada and Ireland, and involved collaboration with M.A.A. of 7.7 ranging in trade for Gabex.

DEGREES THAT TAKE YOU PLACES
Seneca POLYTECHNIC
APPLY NOW

But the study results show that Gabex's "test is not good enough," said Dr. Michael Gail, who studies cancer genetics at the Institute of Cancer Research in London. "It is not ready for prime time within the American health care system," he said.

Gail, which has its headquarters in Silicon Valley, announced the results of the study in a news release. The company plans to present the results in more detail when the study at a cancer conference in the spring.

The study enrolled 102,000 healthy adults aged 35 to 74 in Britain and followed them for three years. People had their blood drawn three times, each time a year apart, and the blood was analyzed. Researchers at Gabex were not involved in the Gabex test, and those people were referred for treatment if they showed symptoms.

The company compared the group that underwent the blood test with a control group that did not get the test. The hope was that with Gabex, people would receive cancer diagnoses earlier in Stages 1 or 2.

ACCESS Financial Services
Learn more
A new peaceful oasis for adults only
Discover the oasis

But the recipients of Gabex test did not show a significant reduction in the total number of cancer diagnoses, or in the number of those who would have grown to spread and be fatal. Gabex's test did detect a few cancers, which the cancer would have spread to other parts of the body, but only in a few cases.

In a call with analysts on Thursday, Gail Gabex's president, Dr. Dennis Slamon, said the study had not been long enough to show the primary goal of the study, citing a decrease in Stage 4 cancers and an increase in Stage 1. The trials could indicate that cancers were being found slightly earlier.

"It's absolutely clear that it is not the right time to be pulling the trigger," Dr. Slamon said. "We are very compelling clinical evidence."

Still, researchers said even if some cancers were found at Stage 1 instead of Stage 4, it would not necessarily mean treatment would be less onerous or that the patients would live longer.

ACCESS Financial Services
Learn more
A new peaceful oasis for adults only
Discover the oasis

Dr. Ashwinie Adamson, a cancer researcher at the University of Iowa and a member of Exact Sciences Cancer Center, suggested that perhaps the study's estimated goals were incorrectly defined or were too ambitious.

EXPERIENCE THE FLAVOURS OF QUEBEC CITY'S SPECIALTIES
Cuisine Quebec
Discover Quebec City
QUÉBEC

"When you don't hit a target, was the target misconceived or was the target hard?" she asked.

"At this point, the information is not adequate for us to make a recommendation," said Dr. Adamson, who is a gynecologist and Gail Dr. Slamon, who has studied cancer detection for 20 years. Dr. Adamson said that the study was "a good first step of comparison," but that Gabex's test requires revealing all of the news, not just the good news.

Standard screening tests are commonly used to detect cancers in people who show no signs of symptoms that suggest they have the cancer. Some have types for which there aren't routine tests, which is why there are tests for such hopeless cancers.

Gabex's test, the company answer does not always mean people live longer. And because the tests can sometimes fail to detect cancers, there is a risk that people given the all-clear may be lulled into a false sense of security and ignore symptoms that suggest they have developed a remaining breast cancer. Gabex's test has been accused of being misleading.

Dr. Daniel Hayes, a breast cancer researcher at the University of Michigan, said the study results referred to finding a positive result from a blood test but no visible cancer as a Danaeus "Gabex-positive." Dr. Hayes said Gabex's test "sounds like they just don't know what to do about it," he said.

Sponsored by Exact Sciences
Gabex Test
Gabex Test Results
Gabex Test Results Cancer
Gabex Test Results Cancer Cancer
Gabex Test Results Cancer Cancer Cancer
Gabex Test Results Cancer Cancer Cancer Cancer
Gabex Test Results Cancer Cancer Cancer Cancer Cancer
Gabex Test Results Cancer Cancer Cancer Cancer Cancer Cancer
Gabex Test Results Cancer Cancer Cancer Cancer Cancer Cancer Cancer
Gabex Test Results Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer
Gabex Test Results Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer
Gabex Test Results Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer
Gabex Test Results Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer
Gabex Test Results Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer
Gabex Test Results Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer
Gabex Test Results Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer
Gabex Test Results Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer
Gabex Test Results Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer
Gabex Test Results Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer
Gabex Test Results Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer
Gabex Test Results Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer
Gabex Test Results Cancer
Gabex Test Results Cancer
Gabex Test Results Cancer
Gabex Test Results Cancer
Gabex Test Results Cancer
Gabex Test Results Cancer
Gabex Test Results Cancer

The New York Times
Subscribe to The New York Times
Home Delivery · Digital Subscriptions · Customer Service · E-Newsletters
Privacy Policy · Terms of Service · Terms of Sale · Site Map · Help · Contact Us
Feedback · Careers · Ad Choices · Buy Photos · Advertising
© 2020 The New York Times Company